Form 4: Adverum Biotechnologies Executive Acquires Shares and Options
SEC Form 4 Filing
Setareh Seyedkazemi, Chief Development Officer of Adverum Biotechnologies, reports acquisition of shares and stock options.
Summary
- Setareh Seyedkazemi, Chief Development Officer of Adverum Biotechnologies, filed a Form 4 detailing changes in beneficial ownership.
- The report indicates the acquisition of 8,125 shares of common stock through the settlement of a restricted stock unit (RSU) grant.
- These RSUs will vest in equal installments on each anniversary of March 1, 2025, over three years, contingent upon continued service.
- Additionally, Ms. Seyedkazemi acquired options to purchase 48,750 shares of common stock at an exercise price of $4.20.
- These options vest over four years from March 1, 2025, with 25% vesting after the first year and the remainder vesting monthly thereafter, also contingent upon continued service.
- The report also notes that Ms. Seyedkazemi owns 14,692 shares of common stock, including shares purchased through the company's employee stock purchase plan.
- A 1-for-10 stock split on March 21, 2024, resulted in a proportionate reduction of the reporting person's shares.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine disclosure of stock and option acquisitions by an executive. While insider buying can be seen as positive, this appears to be part of a standard compensation package.
Positives
- The acquisition of shares and options by a key executive could be interpreted as a sign of confidence in the company's future prospects.
Industry Context
Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and confidence in the company's prospects.
Stakeholder Impact
- The filing provides transparency to shareholders regarding insider transactions.
Key Dates
| Date | Description |
|---|---|
| November 20, 2023 | 600 shares purchased on November 20, 2023, pursuant to the Issuer's 2014 Employee Stock Plan Purchase Plan, as amended and restated. |
| March 21, 2024 | Common Stock of Issuer split 1-for-10. |
| May 20, 2024 | 600 shares purchased on May 20, 2024 pursuant to the Issuer's 2014 Employee Stock Plan Purchase Plan, as amended and restated. |
| November 20, 2024 | 600 shares purchased on November 20, 2024 pursuant to the Issuer's 2014 Employee Stock Plan Purchase Plan, as amended and restated. |
| February 25, 2025 | Date of transaction and grant of stock options. |
| March 1, 2025 | Vesting Commencement Date for RSUs and stock options. |
| February 24, 2035 | Expiration date for stock options. |
Keywords
Adverum Biotechnologies, Seyedkazemi, beneficial ownership, Form 4, stock options, RSU, stock split, ADVM
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.